No connection

Search Results

ABBV vs GDTC

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
GDTC
CytoMed Therapeutics Limited
BEARISH
Price
$1.00
Market Cap
$11.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
GDTC
--
Forward P/E
ABBV
15.42
GDTC
-6.67
P/B Ratio
ABBV
-146.66
GDTC
2.31
P/S Ratio
ABBV
6.5
GDTC
13.74
EV/EBITDA
ABBV
15.27
GDTC
-2.73

Profitability

Gross Margin
ABBV
71.46%
GDTC
89.57%
Operating Margin
ABBV
35.5%
GDTC
-535.25%
Profit Margin
ABBV
4.0%
GDTC
0.0%
ROE
ABBV
137.96%
GDTC
-50.28%
ROA
ABBV
9.59%
GDTC
-29.31%

Growth

Revenue Growth
ABBV
9.1%
GDTC
46.9%
Earnings Growth
ABBV
-88.7%
GDTC
--

Financial Health

Debt/Equity
ABBV
--
GDTC
0.07
Current Ratio
ABBV
0.72
GDTC
5.17
Quick Ratio
ABBV
0.47
GDTC
3.14

Dividends

Dividend Yield
ABBV
3.05%
GDTC
--
Payout Ratio
ABBV
490.15%
GDTC
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
GDTC BEARISH

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Strengths
Strong liquidity position with a Current Ratio of 5.17
Very low leverage (Debt/Equity of 0.07)
High Gross Margin (89.57%) typical of high-potential biotech
Risks
Extreme operational inefficiency with an operating margin of -535.25%
Severe multi-year price erosion (-75% over 3-5 years)
Micro-cap volatility and lack of institutional analyst coverage

Compare Another Pair

ABBV vs GDTC: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and CytoMed Therapeutics Limited (GDTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile